Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 5/20 | 0.59 |
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.58 |
| ▸ | HRH2 | P25021 | 9/20 | 0.58 |
| ▸ | HRH1 | P35367 | 9/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5624212 | 0.94 | MMP2 (0.60) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL8748087 | 0.94 | HRH3 (0.56) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL6731770 | 0.92 | HRH3 (0.58) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL1778067 | 0.92 | HRH3 (0.58) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL26602050 | 0.92 | MMP3 (0.66) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL7978264 | 0.91 | MMP2 (0.60) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL16841044 | 0.90 | HDAC1 (0.67) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL18079151 | 0.90 | HDAC1 (0.67) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL29444063 | 0.90 | HDAC1 (0.67) | MMP3MMP2HRH3HRH2HRH1 | |
| SCHEMBL1714609 | 0.88 | HRH3 (0.54) | MMP3MMP2HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | MMP3 1614/4885MMP2 2741/4885HRH3 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.